260 related articles for article (PubMed ID: 8550830)
1. Inhibition of cyclic 3'-5'-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats.
Cohen AH; Hanson K; Morris K; Fouty B; McMurty IF; Clarke W; Rodman DM
J Clin Invest; 1996 Jan; 97(1):172-9. PubMed ID: 8550830
[TBL] [Abstract][Full Text] [Related]
2. E4021, a selective phosphodiesterase 5 inhibitor, potentiates the vasodilator effect of inhaled nitric oxide in isolated perfused rat lungs.
Ohnishi M; Oka M; Muramatsu M; Sato K; Kira S; Fukuchi Y
J Cardiovasc Pharmacol; 1999 Apr; 33(4):619-24. PubMed ID: 10218733
[TBL] [Abstract][Full Text] [Related]
3. Effect of DMPPO, a phosphodiesterase type 5 inhibitor, on hypoxic pulmonary hypertension in rats.
Eddahibi S; Raffestin B; Le Monnier de Gouville AC; Adnot S
Br J Pharmacol; 1998 Oct; 125(4):681-8. PubMed ID: 9831902
[TBL] [Abstract][Full Text] [Related]
4. [E 4021, a cGMP phosphodiesterase inhibitor, is a selective pulmonary vasodilator in chronically hypoxic pulmonary hypertensive rats].
Yamaguchi K; Oka M; Nishino M; Hanasato N; Kira S; Fukuchi Y
Nihon Kokyuki Gakkai Zasshi; 1998 Jan; 36(1):23-8. PubMed ID: 9611972
[TBL] [Abstract][Full Text] [Related]
5. Cyclic-GMP-binding, cyclic-GMP-specific phosphodiesterase (PDE5) gene expression is regulated during rat pulmonary development.
Sanchez LS; de la Monte SM; Filippov G; Jones RC; Zapol WM; Bloch KD
Pediatr Res; 1998 Feb; 43(2):163-8. PubMed ID: 9475279
[TBL] [Abstract][Full Text] [Related]
6. Potency and mechanism of action of E4021, a type 5 phosphodiesterase isozyme-selective inhibitor, on the photoreceptor phosphodiesterase depend on the state of activation of the enzyme.
D'Amours MR; Granovsky AE; Artemyev NO; Cote RH
Mol Pharmacol; 1999 Mar; 55(3):508-14. PubMed ID: 10051534
[TBL] [Abstract][Full Text] [Related]
7. Low-dose phosphodiesterase inhibition improves responsiveness to inhaled nitric oxide in isolated lungs from endotoxemic rats.
Klein A; Zils U; Bopp C; Gries A; Martin E; Gust R
J Surg Res; 2007 Apr; 138(2):224-30. PubMed ID: 17275845
[TBL] [Abstract][Full Text] [Related]
8. Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity.
Hanson KA; Ziegler JW; Rybalkin SD; Miller JW; Abman SH; Clarke WR
Am J Physiol; 1998 Nov; 275(5):L931-41. PubMed ID: 9815111
[TBL] [Abstract][Full Text] [Related]
9. The cGMP-specific phosphodiesterase inhibitor E4021 dilates the pulmonary circulation.
Dukarm RC; Russell JA; Morin FC; Perry BJ; Steinhorn RH
Am J Respir Crit Care Med; 1999 Sep; 160(3):858-65. PubMed ID: 10471609
[TBL] [Abstract][Full Text] [Related]
10. Postnatal maturation of phosphodiesterase 5 (PDE5) in piglet pulmonary arteries: activity, expression, effects of PDE5 inhibitors, and role of the nitric oxide/cyclic GMP pathway.
Moreno L; Losada B; Cogolludo Al; Lodi F; Lugnier C; Villamor E; Moro M; Tamargo J; Pérez-Vizcaíno F
Pediatr Res; 2004 Oct; 56(4):563-70. PubMed ID: 15295092
[TBL] [Abstract][Full Text] [Related]
11. Chronic hypoxia attenuates cGMP-dependent pulmonary vasodilation.
Jernigan NL; Resta TC
Am J Physiol Lung Cell Mol Physiol; 2002 Jun; 282(6):L1366-75. PubMed ID: 12003794
[TBL] [Abstract][Full Text] [Related]
12. Increased cGMP phosphodiesterase activity mediates renal resistance to ANP in rats with bile duct ligation.
Ni XP; Safai M; Gardner DG; Humphreys MH
Kidney Int; 2001 Apr; 59(4):1264-73. PubMed ID: 11260387
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension.
Murray F; MacLean MR; Pyne NJ
Br J Pharmacol; 2002 Dec; 137(8):1187-94. PubMed ID: 12466227
[TBL] [Abstract][Full Text] [Related]
14. Increased activity of guanosine 3'-5'-cyclic monophosphate phosphodiesterase in the renal tissue of cirrhotic rats with ascites.
Angeli P; Jiménez W; Veggian R; Fasolato S; Volpin R; MacHenzie HS; Craighero R; Libera VD; Sticca A; Arroyo V; Gatta A
Hepatology; 2000 Feb; 31(2):304-10. PubMed ID: 10655250
[TBL] [Abstract][Full Text] [Related]
15. The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide.
Thusu KG; Morin FC; Russell JA; Steinhorn RH
Am J Respir Crit Care Med; 1995 Nov; 152(5 Pt 1):1605-10. PubMed ID: 7582302
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the hemodynamic effects of nitric oxide and endothelium-dependent vasodilators in intact lungs.
Archer SL; Rist K; Nelson DP; DeMaster EG; Cowan N; Weir EK
J Appl Physiol (1985); 1990 Feb; 68(2):735-47. PubMed ID: 2156794
[TBL] [Abstract][Full Text] [Related]
17. Effects of phosphodiesterase inhibition on cortical spreading depression and associated changes in extracellular cyclic GMP.
Wang M; Urenjak J; Fedele E; Obrenovitch TP
Biochem Pharmacol; 2004 Apr; 67(8):1619-27. PubMed ID: 15041479
[TBL] [Abstract][Full Text] [Related]
18. Cyclic GMP potentiation by WIN 58237, a novel cyclic nucleotide phosphodiesterase inhibitor.
Silver PJ; Dundore RL; Bode DC; de Garavilla L; Buchholz RA; van Aller G; Hamel LT; Bacon E; Singh B; Lesher GY
J Pharmacol Exp Ther; 1994 Dec; 271(3):1143-9. PubMed ID: 7996419
[TBL] [Abstract][Full Text] [Related]
19. Effect of cyclic guanosine monophosphate on hypoxic and angiotensin-II-induced pulmonary vasoconstriction.
Fujimoto K; Sakai A; Yoshikawa S; Shinozaki S; Matsuzawa Y; Kubo K; Kobayashi T; Ueda G; Sekiguchi M; Voelkel NF
Lung; 1990; 168(6):333-43. PubMed ID: 2177815
[TBL] [Abstract][Full Text] [Related]
20. A selective type V phosphodiesterase inhibitor, E4021, dilates porcine large coronary artery.
Saeki T; Adachi H; Takase Y; Yoshitake S; Souda S; Saito I
J Pharmacol Exp Ther; 1995 Feb; 272(2):825-31. PubMed ID: 7853200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
